Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last241 to 260 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| People With Crohn's Disease (Cases) vs People Without Crohn's Disease (Controls): Prevalence of Anxiety Episodes (Crohn's Disease) | 262 of 7,557 892 of 30,228 | 0.5 points 0.1 to 1.0 | 37,785 | NCT03836612 Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease |
| People With Crohn's Disease (Cases) vs People Without Crohn's Disease (Controls): Number of People With Depressive Disorder in People With and Without Crohn's Disease | 1,322 of 7,557 3,911 of 30,228 | 4.6 points 3.6 to 5.5 | 37,785 | NCT03836612 Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease |
| Brief Clinician Education vs Clinical Decision Support Nudges and Brief Clinician Education: deaths from any cause | 511 of 18,709 469 of 18,425 | 0.2 points -0.1 to 0.5 | 37,134 | NCT04289753 Behavioral Economics Applications to Geriatrics Leveraging EHRs R33 Trial |
| Cases vs Controls: Number of Participants With Recurrent Depressive Disorder | 1,093 of 7,224 4,305 of 28,880 | 0.2 points -0.7 to 1.2 | 36,104 | NCT04953338 Mental Health Associations With Vitiligo |
| Cases vs Controls: Number of Participants With Anxiety Disorder | 569 of 7,224 2,031 of 28,880 | 0.8 points 0.2 to 1.5 | 36,104 | NCT04953338 Mental Health Associations With Vitiligo |
| Cases vs Controls: Number of Participants With Depressive Episodes | 1,018 of 7,224 4,007 of 28,880 | 0.2 points -0.7 to 1.1 | 36,104 | NCT04953338 Mental Health Associations With Vitiligo |
| NuvaRing vs Combined Oral Contraceptives (COC): serious adverse events | 577 of 17,084 751 of 17,016 | -1.0 points -1.4 to -0.6 | 34,100 | NCT00524771 Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC) |
| Direct Acting Antivirals vs Comparison: deaths from any cause | 77 of 15,524 2,186 of 18,284 | -11.5 points -11.9 to -11.0 | 33,808 | NCT03423641 An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C |
| Male Cases vs Male Controls: Number of New Onset Skin Cancers in the Male Sex Subgroup | 55 of 6,823 383 of 26,936 | -0.6 points -0.9 to -0.3 | 33,759 | NCT04969419 Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo |
| Cases vs Controls: Number of New Onset Skin Cancers in the <45 Age Subgroup | 11 of 6,711 72 of 26,789 | -0.1 points -0.2 to 0.0 | 33,500 | NCT04969419 Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo |
| Group 1: QIV-HD vs Group 2: QIV-SD: Number of Participants With Non-fatal SAEs | 2 of 16,549 0 of 16,544 | 0.0 points -0.0 to 0.0 | 33,093 | NCT04137887 Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older |
| Group 1: QIV-HD vs Group 2: QIV-SD: Number of Participants With Hospitalizations Due to Cardiovascular or Respiratory Diseases | 257 of 16,549 272 of 16,544 | -0.1 points -0.4 to 0.2 | 33,093 | NCT04137887 Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older |
| Group1: QIV-HD vs Group 2: QIV-SD: deaths from any cause | 102 of 16,549 92 of 16,544 | 0.1 points -0.1 to 0.2 | 33,093 | NCT04137887 Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older |
| Group1: QIV-HD vs Group 2: QIV-SD: serious adverse events | 109 of 16,549 98 of 16,544 | 0.1 points -0.1 to 0.2 | 33,093 | NCT04137887 Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older |
| AZD1222 vs Placebo: deaths from any cause | 62 of 21,587 33 of 10,793 | -0.0 points -0.2 to 0.1 | 32,380 | NCT04516746 Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults |
| AZD1222 vs Placebo: serious adverse events | 1,039 of 21,587 467 of 10,793 | 0.5 points -0.0 to 1.0 | 32,380 | NCT04516746 Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults |
| Cervarix Pooled Group vs Engerix-B Pooled Group: Number of Subjects With New Onset of Autoimmune Diseases (NOADs), Retrieved From Care Register for Social Welfare and Health Care (HILMO) | 149 of 14,837 180 of 17,338 | -0.0 points -0.3 to 0.2 | 32,175 | NCT00534638 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents |
| Cervarix Pooled Group vs Engerix-B Pooled Group: Number of Subjects Reporting SAEs Assessed by the Investigator as Possibly Related to Vaccination | 25 of 14,837 30 of 17,338 | -0.0 points -0.1 to 0.1 | 32,175 | NCT00534638 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents |
| Cervarix Pooled Group vs Engerix-B Pooled Group: serious adverse events | 188 of 14,837 152 of 17,338 | 0.4 points 0.2 to 0.6 | 32,175 | NCT00534638 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents |
| Users of DRSP vs Users of LNG: Number of Participants With Venous Thromboembolism (VTE) | 26 of 16,534 25 of 15,428 | -0.0 points -0.1 to 0.1 | 31,962 | NCT00302848 European Active Surveillance Study (EURAS) |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=13
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03836612-970d1725",
"title": "People With Crohn's Disease (Cases) vs People Without Crohn's Disease (Controls): Prevalence of Anxiety Episodes (Crohn's Disease)",
"summary": "262 of 7557 against 892 of 30228; risk difference 0.5 points, 95% interval 0.1 to 1.0; NCT03836612, Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease",
"record": "/library/comparisons/NCT03836612-970d1725",
"nct_id": "NCT03836612",
"kind": "outcome",
"participants": 37785,
"risk_difference": {
"value": 0.005160778086542275,
"lower": 0.0007976147979284988,
"upper": 0.009902806659750787
},
"group_1": "262 of 7,557",
"group_2": "892 of 30,228",
"difference": "0.5 points",
"interval": "0.1 to 1.0",
"trial_title": "Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease"
},
{
"id": "NCT03836612-e6868fdd",
"title": "People With Crohn's Disease (Cases) vs People Without Crohn's Disease (Controls): Number of People With Depressive Disorder in People With and Without Crohn's Disease",
"summary": "1322 of 7557 against 3911 of 30228; risk difference 4.6 points, 95% interval 3.6 to 5.5; NCT03836612, Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease",
"record": "/library/comparisons/NCT03836612-e6868fdd",
"nct_id": "NCT03836612",
"kind": "outcome",
"participants": 37785,
"risk_difference": {
"value": 0.04555379118697897,
"lower": 0.036321689525995904,
"upper": 0.05504996020503928
},
"group_1": "1,322 of 7,557",
"group_2": "3,911 of 30,228",
"difference": "4.6 points",
"interval": "3.6 to 5.5",
"trial_title": "Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=14",
"request_id": "8xak5TF3ryX5MN6E"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant